-
Case Report
-
Korean J Med. 2014;87(3):357-362. Published online September 1, 2014.
DOI: https://doi.org/10.3904/kjm.2014.87.3.357
- 림프종 환자에서 리툭시맙 치료 후에 발생한 저감마글로불린혈증 1예
-
노현진, 공봉한, 김영신, 정윤화, 우인숙, 한치화
-
가톨릭대학교 의과대학 내과학교실
- A Case of Prolonged Hypogammaglobulinemia after Rituximab-Containing Chemotherapy in a Patient with Lymphoma
-
Hyun Jin Noh, Bong Han Gong, Young Sin Kim, Yun Hwa Jung, In Sook Woo, Chi Wha Han
-
Departments of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea
- Corresponding author: Chi Wha Han ,Tel: +82-2-3779-2428, Fax: +82-2-780-3132, Email: cwhan@unitel.co.kr
- Received: February 25, 2013; Revised: March 6, 2013 Accepted: November 11, 2013.
- 저자들은 B세포림프종 환자에서 rituximab이 포함된 항암 치료 후 2년 이상 지속된 저감마글로불린혈증을 경험하였기에 문헌고찰과 함께 보고한다.
߽ɾ :비호지킨림프종; 리툭시맙; 면역글로불린 G 결핍
- Abstract
- Rituximab, an anti-CD20 monoclonal antibody, is an effective target agent against the B lymphocytes in B-cell lymphoid malignancies and various lymphoproliferative diseases. Moreover, the toxicity of rituximab is less severe than that of conventional cytotoxic agents, which has promoted the widespread application of rituximab in the treatment of B-cell lymphoma. However, depletion of B lymphocytes by rituximab, which leads to secondary hypogammaglobulinemia, can cause deterioration of humoral immunity. Although immune reconstitution after hematopoietic stem cell transplantation is known to prevent prolonged hypogammaglobulinemia, very few cases of long-standing hypogammaglobulinemia have been reported. We report herein a case of prolonged hypogammaglobulinemia after rituximab-containing chemotherapy and splenectomy in a patient with non-Hodgkin’s lymphoma and discuss the clinical significance and pathogenetic mechanism of this phenomenon with a literature review.
Keywords :Non-Hodgkin’s lymphoma, Rituximab, IgG deficiency
